Skip to Main Content

Author Details

Carmen Criscitiello
University of Milano
2008
167
42
PMIDPaper TitleJournal TitlePublished Year
37983586Cardiotoxicity of Agents Used in Patients With Breast Cancer.JCO Oncol Pract2024
37669224Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience.Oncologist2024
37715957Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.Oncologist2024
37548439Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.Oncologist2024
36660432Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers.Front Mol Biosci2023
37864956ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.Cancer Treat Rev2023
37595344Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.Crit Rev Oncol Hematol2023
37913680Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.Eur J Cancer2023
37665782Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.Oncologist2023
37903774Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.NPJ Breast Cancer2023
37704501Variant allele frequency: a decision-making tool in precision oncology?Trends Cancer2023
37890353Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.Eur J Cancer2023
37783318The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.Crit Rev Oncol Hematol2023
37684252Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.NPJ Breast Cancer2023
37639757Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.Cancer Treat Rev2023
37291235Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer.NPJ Breast Cancer2023
37021548Metaplastic breast cancer: an all-round multidisciplinary consensus.Eur J Cancer Prev2023
36989828Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.Eur J Cancer2023
37146385Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?Cancer Treat Rev2023
36980181Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation.Cells2023
37372340Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management.Genes (Basel)2023
36971965HER2-Low Breast Cancer: a New Subtype?Curr Treat Options Oncol2023
37069173Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.NPJ Breast Cancer2023
37473517Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials.Cancer Treat Rev2023
36996620Future potential targets of antibody-drug conjugates in breast cancer.Breast2023
36801623Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.Eur J Cancer2023
36900178Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution.Cancers (Basel)2023
36527795Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care.Cancer Treat Rev2023
34229592Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology.Anticancer Agents Med Chem2022
35372498HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.Front Mol Biosci2022
35465733A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancer.Future Oncol2022
35696887Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?Eur J Cancer2022
35565264Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives.Cancers (Basel)2022
36579519PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative.J Pers Med2022
36627895Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls.Cancer Drug Resist2022
36140761Breast Cancer Genetics: Diagnostics and Treatment.Genes (Basel)2022
36379199PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.Breast2022
34953200Targeting brain metastases in breast cancer.Cancer Treat Rev2022
35127539Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials.Front Oncol2022
35032815Evolution of low HER2 expression between early and advanced-stage breast cancer.Eur J Cancer2022
35272131How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?ESMO Open2022
33482345Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.Crit Rev Oncol Hematol2021
33493979Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis.Eur J Cancer2021
33878560Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis.Cancer Treat Rev2021
33711697Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations.Breast2021
33676293Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.ESMO Open2021
33509252Antibody-drug conjugates in solid tumors: a look into novel targets.J Hematol Oncol2021
33842357<i>PIK3CA</i> Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.Front Oncol2021
33838532Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.ESMO Open2021
33578759Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients.Genes (Basel)2021
  • 1 - 50 of 167

Recommended Authors

Leen Slaets
50148Janssen Pharmaceutica NV
Career Start Year 2014
Number of shared co-authors 3
Martin Sj??str??m
University of California-San Francisco
Career Start Year 2013
Number of shared co-authors 0
Yin Liu
Fudan University Shanghai Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 4
Theodora Goulioti
Career Start Year 2009
Number of shared co-authors 5
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 1
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 4
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 0
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 8
Carolien H M van Deurzen
Erasmus MC Cancer Institute
Career Start Year 2004
Number of shared co-authors 7
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 4
Peter A Fasching
Otto-Friedrich-University Bamberg
Career Start Year 2002
Number of shared co-authors 10
Matthew P Goetz
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 9
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 6
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 4
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 1
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 4
Carolien P Schr??der
University of Groningen, University Medical Center Groningen
Career Start Year 1995
Number of shared co-authors 2
Barbro Linderholm
Sahlgrenska University Hospital
Career Start Year 1994
Number of shared co-authors 7
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 5
Kelly K Hunt
The University of Texas MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 3
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 1
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 6
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 6
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 7
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Career Start Year 1987
Number of shared co-authors 10
Eric P Winer
Dana-Farber Cancer Institute
Career Start Year 1985
Number of shared co-authors 7
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 2
Larry Norton
Memorial Sloan Kettering Cancer Center
Career Start Year 1976
Number of shared co-authors 6
Gabriel N Hortobagyi
The University of Texas MD Anderson Cancer Center
Career Start Year 1976
Number of shared co-authors 8

Collaborators

Giuseppe Curigliano
University of Milan
Co-authored papers 117
Chiara Corti
University of Milano
Co-authored papers 22
Nicola Fusco
IEO European Institute of Oncology IRCCS
Co-authored papers 17
Christos Sotiriou
Co-authored papers 10
Alberto Zambelli
IRCCS Humanitas Research Hospital
Co-authored papers 4
William F Symmans
Co-authored papers 4
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 3
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers 3
Caterina Marchi??
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Co-authored papers 3
Matthias Preusser
Medical University of Vienna
Co-authored papers 3
Sandra Demaria
Weill Cornell Medical College
Co-authored papers 3
David L Rimm
Yale University School of Medicine
Co-authored papers 3
Andrea L Richardson
Co-authored papers 3
Prudence A Russell
St Vincent's Hospital
Co-authored papers 2
Melinda E Sanders
Co-authored papers 2
Stephen M Hewitt
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 2
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Isabel T Rubio
Clinica Universidad de Navarra, Cancer Center Universidad de Navarra
Co-authored papers 2
Laura Riva
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 2
Meredith M Regan
Co-authored papers 2
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Lisa A Carey
Co-authored papers 2
Sara M Tolaney
Dana-Farber Cancer Institute
Co-authored papers 2
Sunil R Lakhani
University of Queensland
Co-authored papers 2
Johannes A Hainfellner
Medical University of Vienna
Co-authored papers 2
Bibhusal Thapa
Northern Hospital
Co-authored papers 2
Lajos Pusztai
Co-authored papers 2
Paula I Gonzalez-Ericsson
Co-authored papers 2
José Baselga
Co-authored papers 2
Release 1.2